Avexis, which is commercialising research from Ohio State University and Nationwide Children's Hospital, has been acquired by Novartis for $8.7bn.

The drug developer, which is targeting chronic inflammation-related diseases, has raised series A cash two years after it spun out of Selvita.

UC Investment Office-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.

SR One-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

Roche and Novo-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

Dementia Discovery Fund, backed by more than half a dozen corporates, reached its final close after AARP supplied $60m.

Amgen Ventures, Brace Pharma Capital and Alexandria Venture Investments all invested in the genome editing technology provider.

Launched in September 2017, Spin-Off Austria supports academics looking to establish spinouts and has selected the first eight projects.

IP Group and Penn Medicine have both returned to back a series A round for Carisma Therapeutics, the Pennsylvania spinout formerly known as Carma.